POLYPOIDAL CHOROIDAL VASCULOPATHY
Authors:
- Adrian H.C. KohAKAdrian H.C. Koh
- Lee-Jen ChenLCLee-Jen Chen
- Shih-Jen ChenSCShih-Jen Chen
- Youxin ChenYCYouxin Chen
- Anantharam GiridharAGAnantharam Giridhar
- Tomohiro IidaTITomohiro Iida
- Hakyoung KimHKHakyoung Kim
- Timothy Yuk Yau LaiTLTimothy Yuk Yau Lai
- Won Ki LeeWLWon Ki Lee
- Xiaoxin LiXLXiaoxin Li
- Tock Han LimTLTock Han Lim
- Paisan RuamviboonsukPRPaisan Ruamviboonsuk
- 1 April 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (4) , 686-716
Abstract
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment. A panel of experts analyzed a systematic literature search on PCV together with results of the EVEREST trial, the only published randomized controlled clinical trial in PCV. At a subsequent Roundtable meeting, recommendations for the management of PCV were agreed based on this analysis and their own expert opinion. Diagnosis of PCV should be based on early-phase nodular hyperfluorescence from choroidal vasculature visualized using indocyanine green angiography. Recommended initial treatment of juxtafoveal and subfoveal PCV is either indocyanine green angiography-guided verteporfin photodynamic therapy or verteporfin photodynamic therapy plus 3 × 0.5 mg ranibizumab intravitreal injections 1 month apart. If there is incomplete regression of polyps by indocyanine green angiography, eyes should be retreated with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic therapy plus ranibizumab. If there is complete regression of polyps by indocyanine green angiography, but there is leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, eyes should be retreated with ranibizumab. Practical guidance on the clinical management of PCV is proposed based on expert evaluation of current evidence.Keywords
This publication has 162 references indexed in Scilit:
- Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathyEye, 2011
- Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathyJapanese Journal of Ophthalmology, 2011
- Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathyEye, 2011
- Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathyJapanese Journal of Ophthalmology, 2011
- Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal VasculopathyJournal of Ophthalmology, 2011
- Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2009
- Photodynamic therapy for polypoidal choroidal vasculopathy: Vaso-occlusive effect on the branching vascular network and origin of recurrenceJapanese Journal of Ophthalmology, 2008
- Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patientsJapanese Journal of Ophthalmology, 2008
- Photodynamic Therapy for Age-Related Macular Degeneration in Japanese Patients: Results After One YearJapanese Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006